Gershenson D - Search Results

1

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Hartmann LC, et al. Among authors: gershenson d. Clin Cancer Res. 2005 Mar 15;11(6):2149-55. doi: 10.1158/1078-0432.CCR-04-1673. Clin Cancer Res. 2005. PMID: 15788660

2

Serous ovarian tumors of low malignant potential with peritoneal implants.

Gershenson DM, Silva EG. Gershenson DM, et al. Cancer. 1990 Feb 1;65(3):578-85. doi: 10.1002/1097-0142(19900201)65:3<578::aid-cncr2820650332>3.0.co;2-n. Cancer. 1990. PMID: 2297647

3

Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy.

Robey SS, Silva EG, Gershenson DM, McLemore D, el-Naggar A, Ordonez NG. Robey SS, et al. Among authors: gershenson dm. Cancer. 1989 Mar 1;63(5):839-47. doi: 10.1002/1097-0142(19890301)63:5<839::aid-cncr2820630508>3.0.co;2-u. Cancer. 1989. PMID: 2644014

4

Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience.

Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Burke TW, Morris M, Kavanagh JJ, Warner D, Wharton JT. Gershenson DM, et al. Cancer. 1993 Jan 15;71(2 Suppl):638-43. doi: 10.1002/cncr.2820710223. Cancer. 1993. PMID: 8420688

5

Ovarian serous borderline tumors with invasive peritoneal implants.

Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C. Gershenson DM, et al. Cancer. 1998 Mar 15;82(6):1096-103. Cancer. 1998. PMID: 9506355

6

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.

Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT. Gershenson DM, et al. Gynecol Oncol. 1998 Sep;70(3):404-9. doi: 10.1006/gyno.1998.5130. Gynecol Oncol. 1998. PMID: 9790795 Clinical Trial.

7

Serous borderline tumors of the ovary with noninvasive peritoneal implants.

Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C. Gershenson DM, et al. Cancer. 1998 Nov 15;83(10):2157-63. doi: 10.1002/(sici)1097-0142(19981115)83:10<2157::aid-cncr14>3.0.co;2-d. Cancer. 1998. PMID: 9827720

8

Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?

Mills GB, Schmandt R, Gershenson D, Bast RC. Mills GB, et al. Among authors: gershenson d. Clin Cancer Res. 1999 Sep;5(9):2286-8. Clin Cancer Res. 1999. PMID: 10499594 No abstract available.

9

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.

Wolf JK, Mills GB, Bazzet L, Bast RC Jr, Roth JA, Gershenson DM. Wolf JK, et al. Among authors: gershenson dm. Gynecol Oncol. 1999 Nov;75(2):261-6. doi: 10.1006/gyno.1999.5565. Gynecol Oncol. 1999. PMID: 10525383

10

Outcome and reproductive function after chemotherapy for ovarian dysgerminoma.

Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Brewer M, et al. Among authors: gershenson dm. J Clin Oncol. 1999 Sep;17(9):2670-75. doi: 10.1200/JCO.1999.17.9.2670. J Clin Oncol. 1999. PMID: 10561340

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

518 results

Search Page

Filters